PubRank

C W Francis

Author PubWeight™ 100.11‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007 3.22
2 Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis. J Lab Clin Med 1992 2.22
3 Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res 2010 1.93
4 Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor-2 (FGF-2). J Thromb Haemost 2007 1.92
5 Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood 2000 1.74
6 Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 2008 1.70
7 Cavitational mechanisms in ultrasound-accelerated thrombolysis at 1 MHz. Ultrasound Med Biol 2000 1.55
8 Ultrasound reversibly disaggregates fibrin fibers. Thromb Haemost 1997 1.40
9 Diagnosis of femoropopliteal venous thrombosis with MR imaging: a comparison of four MR pulse sequences. AJR Am J Roentgenol 1990 1.39
10 Characterization of ultrasound-potentiated fibrinolysis in vitro. Blood 1993 1.36
11 A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg 1994 1.26
12 Binding of basic fibroblast growth factor to fibrinogen and fibrin. J Biol Chem 1998 1.25
13 Fibrin induces release of von Willebrand factor from endothelial cells. J Clin Invest 1987 1.22
14 Enhancement of fibrinolysis with 40-kHz ultrasound. Circulation 1998 1.19
15 Enzymatic degradation of the factor-VIII-von-Willebrand protein: a unique tryptic fragment with ristocetin cofactor activity. Blood 1980 1.18
16 Rapid lysis of coronary artery thrombi with anisoylated plasminogen: streptokinase activator complex. Treatment by bolus intravenous injection. Ann Intern Med 1986 1.17
17 Polonium-210 analyses of vegetables, cured and uncured tobacco, and associated soils. Science 1965 1.11
18 Structural studies of the functional heterogeneity of von Willebrand protein polymers. Blood 1981 1.10
19 Relationship of the lytic state to successful reperfusion with standard- and low-dose intracoronary streptokinase. Circulation 1985 1.08
20 Two-step warfarin therapy. Prevention of postoperative venous thrombosis without excessive bleeding. JAMA 1983 1.05
21 Flow through clots determines the rate and pattern of fibrinolysis. Thromb Haemost 1994 1.04
22 Binding of tissue-plasminogen activator to fibrin: effect of ultrasound. Blood 1998 1.04
23 Effect of 40-kHz ultrasound on acute thrombotic ischemia in a rabbit femoral artery thrombosis model: enhancement of thrombolysis and improvement in capillary muscle perfusion. Circulation 2000 1.04
24 Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 1983 1.02
25 Plasmic degradation of crosslinked fibrin. I. Structural analysis of the particulate clot and identification of new macromolecular-soluble complexes. Blood 1980 1.02
26 Ultrasound enhancement of thrombolysis and reperfusion in vitro. J Am Coll Cardiol 1993 1.01
27 Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med 2001 1.00
28 Anticardiolipin antibodies and recurrent coronary events: a prospective study of 1150 patients. Thrombogenic Factors, and Recurrent Coronary Events Investigators. Circulation 2000 0.99
29 Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential. J Lab Clin Med 1992 0.99
30 Hemolysis in vivo from exposure to pulsed ultrasound. Ultrasound Med Biol 1997 0.98
31 Fibrinogen binding to human blood platelets: effect of gamma chain carboxyterminal structure and length. Blood 1986 0.98
32 Transport processes in fibrinolysis and fibrinolytic therapy. Thromb Haemost 1996 0.97
33 Structural studies of fibrinolysis by electron microscopy. Blood 1998 0.97
34 Low-intensity ultrasound increases endothelial cell nitric oxide synthase activity and nitric oxide synthesis. J Thromb Haemost 2004 0.97
35 Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. Semin Thromb Hemost 2001 0.95
36 Response of C-reactive protein and serum amyloid A to influenza A infection in older adults. J Infect Dis 2001 0.95
37 Challenges of rare disease research: limited patients and competing priorities. Haemophilia 2011 0.94
38 Ultrasound increases flow through fibrin gels. Thromb Haemost 1995 0.93
39 Relation of factor V Leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery. Ann Intern Med 1998 0.93
40 Effects of lipids and lipid-lowering therapy on hemostatic factors in patients with myocardial infarction. J Thromb Haemost 2004 0.92
41 Principles of access to health care. Access to Health Care Task Force, American Heart Association. Circulation 1993 0.92
42 Cell proliferation on fibrin: modulation by fibrinopeptide cleavage. Blood 1995 0.92
43 Neuropathologic findings in a Guillain-Barré patient with strokes after IVIg therapy. Neurology 2002 0.92
44 Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost 2003 0.92
45 Heparin-binding domain of fibrin mediates its binding to endothelial cells. Arterioscler Thromb Vasc Biol 1996 0.91
46 Demonstration of a large molecular weight variant of the gamma chain of normal human plasma fibrinogen. J Biol Chem 1980 0.91
47 Spreading of platelets on fibrin is mediated by the amino terminus of the beta chain including peptide beta 15-42. Blood 1993 0.91
48 Lower risk of thromboembolic disease after total hip replacement with non-cemented than with cemented prostheses. Lancet 1986 0.90
49 Concepts of clot lysis. Annu Rev Med 1986 0.89
50 Acceleration of fibrinolysis by ultrasound in a rabbit ear model of small vessel injury. Thromb Res 1994 0.89
51 Potentiation of endothelial cell proliferation by fibrin(ogen)-bound fibroblast growth factor-2. J Biol Chem 1999 0.89
52 Determination of the topology of factor XIIIa-induced fibrin gamma-chain cross-links by electron microscopy of ligated fragments. J Biol Chem 1993 0.88
53 Plasmic degradation of crosslinked fibrin. Characterization of new macromolecular soluble complexes and a model of their structure. J Clin Invest 1980 0.88
54 Plasmin degradation of cross-linked fibrin. Ann N Y Acad Sci 1983 0.88
55 Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 2001 0.88
56 Quantitation of venous clot lysis with the D-dimer immunoassay during fibrinolytic therapy requires correction for soluble fibrin degradation. Circulation 1990 0.87
57 FGF-2 but not FGF-1 binds fibrin and supports prolonged endothelial cell growth. J Thromb Haemost 2003 0.87
58 Comparison of structures of various human fibrinogens and a derivative thereof by a study of the kinetics of release of fibrinopeptides. Biochemistry 1984 0.87
59 Ultrasound enhancement of rabbit femoral artery thrombolysis. Cardiovasc Surg 1997 0.87
60 15-deoxy-Delta12,14 prostaglandin J2-induced heme oxygenase-1 in megakaryocytes regulates thrombopoiesis. J Thromb Haemost 2008 0.86
61 Structural and chromatographic heterogeneity of normal plasma fibrinogen associated with the presence of three gamma-chain types with distinct molecular weights. Biochim Biophys Acta 1983 0.86
62 Endothelial cell spreading on fibrin requires fibrinopeptide B cleavage and amino acid residues 15-42 of the beta chain. J Clin Invest 1992 0.86
63 Thrombolytic therapy for acute transmural myocardial infarction. Intracoronary versus intravenous. Am J Med 1984 0.86
64 Magnetic resonance imaging of blood and clots in vitro. Invest Radiol 1990 0.86
65 Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis. Am J Med 1990 0.85
66 Structural studies of fibrinolysis by electron and light microscopy. Thromb Haemost 1999 0.85
67 Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia. J Thromb Haemost 2010 0.85
68 The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects. PPAR Res 2008 0.85
69 Geologic migration potentials of technetium-99 and neptunium-237. Science 1979 0.85
70 The C-terminal sequences of the gamma 57.5 chain of human fibrinogen constitute a plasmin sensitive epitope that is exposed in crosslinked fibrin. Blood 1989 0.83
71 Demonstration of in situ fibrin degradation in pathologic thrombi. Blood 1984 0.83
72 Megakaryocyte and hepatocyte origins of human fibrinogen biosynthesis exhibit hepatocyte-specific expression of gamma chain-variant polypeptides. Blood 1989 0.83
73 Mediation of fibrin-induced release of von Willebrand factor from cultured endothelial cells by the fibrin beta chain. J Clin Invest 1989 0.82
74 Effect of acoustic cavitation on platelets in the presence of an echo-contrast agent. Ultrasound Med Biol 1998 0.82
75 Embolic complications of calf thrombosis following total hip arthroplasty. J Arthroplasty 1993 0.82
76 Fibrinogen and fibrin protect fibroblast growth factor-2 from proteolytic degradation. Thromb Haemost 2000 0.81
77 Ultrasound accelerates urokinase-induced thrombolysis and reperfusion. Am Heart J 1994 0.81
78 Physiologic regulation and pathologic disorders of fibrinolysis. Hum Pathol 1987 0.81
79 A molecular model of plasmic degradation of crosslinked fibrin. Semin Thromb Hemost 1982 0.81
80 Plasmic degradation modulates activity of fibrinogen-bound fibroblast growth factor-2. J Thromb Haemost 2003 0.81
81 Fibrinogen binding potentiates FGF-2 but not VEGF induced expression of u-PA, u-PAR, and PAI-1 in endothelial cells. J Thromb Haemost 2004 0.80
82 Multimer size dependence of von Willebrand factor binding to crosslinked or noncrosslinked fibrin. Blood 1990 0.80
83 Reversal of multiorgan system dysfunction in sickle cell disease with plasma exchange. Acta Anaesthesiol Scand 1997 0.80
84 Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction. Circulation 1987 0.79
85 Detection of circulating crosslinked fibrin derivatives by a heat extraction-SDS gradient gel electrophoretic technique. Blood 1979 0.79
86 Heparin-induced thrombocytopenia. Blood Rev 1999 0.79
87 Purification and functional characterization of homodimeric gamma B-gamma B fibrinogen from rat plasma. Blood 1993 0.79
88 Dose-ranging studies of anisoylated plasminogen streptokinase activator complex. Studies in healthy volunteers and in patients with acute myocardial infarction. Drugs 1987 0.78
89 Plasminogen depletion during streptokinase treatment or two-chain urokinase incubation correlates with decreased clot lysability ex vivo and in vitro. Thromb Haemost 1993 0.78
90 Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura. A 10-year experience at a single institution. Arch Intern Med 1992 0.78
91 Specific identification of fibrin polymers, fibrinogen degradation products, and crosslinked fibrin degradation products in plasma and serum with a new sensitive technique. Blood 1985 0.78
92 On the conversion of high molecular weight urokinase to the low molecular weight form by plasmin. Thromb Res 1981 0.78
93 Primary fibrinolysis during supraceliac aortic clamping. J Vasc Surg 1997 0.78
94 Markers of hemostatic activation in affected coronary arteries during angioplasty. Thromb Haemost 1994 0.77
95 Purification of three gamma-chains with different molecular weights from normal human plasma fibrinogen. Biochim Biophys Acta 1984 0.77
96 Nomenclature of quantities and units in thrombosis and haemostasis (recommendation 1993). A Collaborative project of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (ISTH/SSC) and the Commission/Committee on Quantities and Units (in Clinical Chemistry) of the International Union of Pure and Applied Chemistry-International Federation of Clinical Chemistry (IUPAC-IFCC/CQU(CC)). Thromb Haemost 1994 0.77
97 Plasma and platelet fibrinogen differ in gamma chain content. Thromb Haemost 1984 0.77
98 Calcium modulates plasmin cleavage of the fibrinogen D fragment gamma chain N-terminus: mapping of monoclonal antibody J88B to a plasmin sensitive domain of the gamma chain. Biochim Biophys Acta 1996 0.77
99 Evaluation of mild bleeding disorders and easy bruising. Blood Rev 1994 0.76
100 Protein S declines during winter respiratory infections. J Thromb Haemost 2003 0.76
101 Degradation of cross-linked fibrin by human leukocyte proteases. J Lab Clin Med 1986 0.76
102 The role of soluble cross-linked fibrin in D dimer immunoreactivity of plasmic digests. J Lab Clin Med 1989 0.76
103 Comparison of native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant prophylaxis. Circulation 1993 0.76
104 Prothrombotic changes in hemostatic parameters and C-reactive protein in the elderly with winter acute respiratory tract infections. Thromb Haemost 2001 0.76
105 Comparison of a chromogenic prothrombin time with clotting prothrombin time in the assessment of clinical coagulation deficiencies. Am J Clin Pathol 1985 0.75
106 The relative uptake of 237Pu(IV) and Pu(VI) oxidation states from water by bush beans. Health Phys 1978 0.75
107 Two-step warfarin therapy for the prophylaxis of venous thrombosis after elective surgery. Adv Exp Med Biol 1987 0.75
108 A soluble fibrin standard: comparable dose-response with immunologic and functional assays. Thromb Haemost 1999 0.75
109 Antithrombin III/low-dose heparin in the prevention of deep-vein thrombosis after total knee arthroplasty. A preliminary report. Clin Orthop Relat Res 1989 0.75
110 Potentiation of wheat germ agglutinin aggregation of platelets by von Willebrand protein and by a 116,000 molecular weight tryptic fragment. Thromb Res 1983 0.75
111 Prevalence and clinical implications of heparin-associated false positive tests for serum fibrin(ogen) degradation products. Am J Clin Pathol 1986 0.75
112 Thrombolytic therapy for arterial thrombosis. Curr Opin Hematol 1999 0.75
113 Effects of ionic and nonionic radiographic contrast agents on endothelial cells in vitro. J Lab Clin Med 1992 0.75
114 Thrombotic thrombocytopenic purpura: recovery after splenectomy associated with persistence of abnormally large von Willebrand factor multimers. Am J Hematol 1985 0.75
115 Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction. Circulation 1986 0.75
116 Posttransfusion purpura secondary to an alloantibody reactive with HPA-5a (Br(b)). Transfusion 2001 0.75
117 Reactivity of soluble fibrin assays with plasmic degradation products of fibrin and in patients receiving fibrinolytic therapy. Thromb Haemost 1999 0.75
118 Secretion of plasminogen activator by the human macrophage-like cell line, GCT: separation from colony-stimulating and erythropoiesis-enhancing activities. Br J Haematol 1982 0.75
119 Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non-diabetic patients with coronary artery disease. J Thromb Haemost 2007 0.75
120 Prolonged remission after life-threatening gastrointestinal hemorrhage from coexistent angiodysplasia and acquired bleeding diathesis. Am J Hematol 1988 0.75
121 Disseminated intravascular coagulation and status epilepticus. Neurology 1998 0.75
122 An assessment of regional versus systemic thrombolytic treatment of peripheral and coronary artery thrombosis. Prog Hemost Thromb 1984 0.75
123 Specific identification of urinary fibrinogen, fibrinogen degradation products, and cross-linked fibrin degradation products in renal diseases and after renal allotransplantation. J Lab Clin Med 1986 0.75
124 Physiological balance of haemostasis and bleeding. Drugs 1987 0.75
125 Heterogeneity of normal human fibrinogen due to two high molecular weight variant gamma chains. Ann N Y Acad Sci 1983 0.75
126 Plasma crosslinked fibrin polymers: quantitation based on tissue plasminogen activator conversion to D-dimer and measurement in normal and patients with acute thrombotic disorders. Blood 1992 0.75
127 Terminology for macromolecular plasmic derivatives of crosslinked fibrin. Thromb Haemost 1987 0.75
128 Plasmic degradation of fibrin rapidly decreases platelet adhesion and spreading. Blood 1994 0.75
129 Radioisotope techniques in delineation of the environmental behavior of cadmium. Environ Qual Saf 1976 0.75
130 Relation of plasma D-dimer concentrations to coronary artery reperfusion before and after thrombolytic treatment in patients with acute myocardial infarction. Am J Cardiol 1989 0.75